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A B S T R A C T
Purpose
Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors,
and has shown activity in men with previously treated metastatic castration-resistant prostate cancer
(mCRPC). This blinded phase III trial compared cabozantinib with prednisone in patients with mCRPC.
Patients and Methods
Men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide were randomly
assigned at a two-to-one ratio to cabozantinib 60mg once per day or prednisone 5mg twice per day.
The primary end point was overall survival (OS). Bone scan response (BSR) at week 12 as assessed
by independent review committee was the secondary end point; radiographic progression-free
survival (rPFS) and effects on circulating tumor cells (CTCs), bone biomarkers, serum prostate-
speciﬁc antigen (PSA), and symptomatic skeletal events (SSEs) were exploratory assessments.
Results
A total of 1,028 patients were randomly assigned to cabozantinib (n = 682) or prednisone (n = 346).
Median OS was 11.0 months with cabozantinib and 9.8 months with prednisone (hazard ratio, 0.90;
95% CI, 0.76 to 1.06; stratiﬁed log-rank P = .213). BSR at week 12 favored cabozantinib (42% v 3%;
stratiﬁed Cochran-Mantel-Haenszel P , .001). rPFS was improved in the cabozantinib group
(median, 5.6 v 2.8 months; hazard ratio, 0.48; 95% CI, 0.40 to 0.57; stratiﬁed log-rank P , .001).
Cabozantinib was associated with improvements in CTC conversion, bone biomarkers, and
post–random assignment incidence of SSEs but not PSA outcomes. Grade 3 to 4 adverse events
and discontinuations because of adverse events were higher with cabozantinib than with predni-
sone (71% v 56% and 33% v 12%, respectively).
Conclusion
Cabozantinib did not signiﬁcantly improve OS compared with prednisone in heavily treated patients
with mCRPC and progressive disease after docetaxel and abiraterone and/or enzalutamide.
Cabozantinib had some activity in improving BSR, rPFS, SSEs, CTC conversions, and bone bio-
markers but not PSA outcomes.
J Clin Oncol 34:3005-3013. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Prostate cancer is a leading cause of cancer
mortality in men worldwide.1 Nearly all prostate
cancer–speciﬁc deaths occur after the develop-
ment of metastatic castration-resistant prostate
cancer (mCRPC).2 Approximately 90% of pa-
tients with mCRPC develop bone metastases,
the predominant cause of morbidity in this
population.3-6
Docetaxel is standard ﬁrst-line chemotherapy
formCRPCbased on improvements in progression-
free (PFS) and overall survival (OS) compared with
mitoxantrone plus prednisone.3,7,8 Two andro-
gen pathway inhibitors, abiraterone acetate and
enzalutamide, improved PFS and OS in patients
with mCRPC when administered before9,10 or
after chemotherapy.11,12 Signiﬁcant OS beneﬁt
in patients with mCRPC has also been reported
with sipuleucel-T, an autologous active cellular
immunotherapy, radium-223, and cabazitaxel in
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combination with prednisone after progression during treatment
with docetaxel.13-15 However, despite recent advances in clini-
cal management, the prognosis for patients with mCRPC re-
mains poor.16,17
The receptor tyrosine kinaseMETand the vascular endothelial
growth factor (VEGF) signaling pathways seem to have important
roles in prostate cancer development and progression.18 MET
expression in prostate cancer was greater in bone metastases than
in primary tumors and lymph node metastases.18-20 The VEGF
pathway regulates cell proliferation, migration, differentiation, and
survival through expression on osteoblasts and osteoclasts. Both
METand VEGF are thought to be involved in bone formation and
remodeling.18-20
Cabozantinib is an orally bioavailable inhibitor of tyrosine
kinases, including MET and VEGF receptor 2. Cabozantinib has
shown activity in preclinical models of many tumor types, in-
cluding prostate cancer.21-24 In a phase II, placebo-controlled,
randomized discontinuation trial, cabozantinib demonstrated
preliminary evidence of activity in multiple tumor types, including
prostate cancer.25 In patients with mCRPC, cabozantinib was
associated with improvement in PFS (hazard ratio [HR], 0.12;
P , .001) and reductions in soft tissue lesions, bone turnover
markers, pain, and narcotic use; the observed safety proﬁle was
consistent with other VEGF tyrosine kinase inhibitors (TKIs).25 In
a subsequent nonrandomized expansion cohort of patients with
mCRPC who had bone metastases and disease progression after
docetaxel, cabozantinib (100 or 40 mg per day) resulted in dra-
matic improvement in bone scans, pain, analgesic use, measurable
soft tissue disease, circulating tumor cell (CTC) conversion, and
bone biomarkers.26,27
On the basis of the promising clinical activity observed in
patients with previously treated mCRPC, we conducted a phase III
study of cabozantinib versus prednisone in men with mCRPC,
bone metastases, and disease progression after docetaxel and
abiraterone acetate and/or enzalutamide. The primary end point
was OS, and bone scan response (BSR) at 12 weeks was the key
secondary end point.
PATIENTS AND METHODS
Patients
The study enrolled patients age 18 years or older with mCRPC who
had bone metastases and disease progression after docetaxel and abir-
aterone acetate and/or enzalutamide. There was no limit on the number of
prior anticancer treatments. Eligible patients had documented histologic
or cytologic diagnosis of adenocarcinoma of the prostate, serum testos-
terone levels lower than 1.75 nmol/L, and evidence of bone metastases
related to prostate cancer on bone scans from a protocol-credentialed
scanner within 28 days before random assignment. Disease progression
after prior therapy was deﬁned as prostate-speciﬁc antigen (PSA) pro-
gression according to modiﬁed Prostate CancerWorking Group 2 criteria28
or radiographic progression in soft tissue or bone lesions. Eligible patients
had an Eastern Cooperative Oncology Group performance status (ECOG
PS) of 0 to 2 and adequate organ and bone marrow function. Exclusion
criteria are summarized in the Appendix (online only).
The study was approved by the institutional review board or ethics
committee at each center and was conducted in accordance with Good
Clinical Practice guidelines and the Declaration of Helsinki. An in-
dependent data monitoring committee monitored the study.
Study Design
This was a phase III, multicenter, randomized, double-blind con-
trolled trial. Patients were randomly assigned at a two-to-one ratio to either
cabozantinib or prednisone. Random assignment was stratiﬁed by prior
cabazitaxel (yes v no), baseline pain severity (worst pain by Brief Pain
Inventory item 3 of , 4 v $ 4), and ECOG PS (0 to 1 v 2). Random
assignment and blinding procedures are summarized in the Appendix.
Cabozantinib was administered orally at 60 mg once per day along
with oral prednisone-matched placebo administered twice per day.
Prednisone was administered orally at 5 mg twice per day along with oral
cabozantinib-matched placebo administered once per day. Patients con-
tinued study treatment as long as clinical beneﬁt was experienced as
determined by the investigator and as long as they did not experience
unacceptable toxicity or meet other protocol-speciﬁed criteria. Patients
were observed until death or until the sponsor’s decision to no longer
collect these data.
Dose reductions (from 60 to 40 mg and 40 to 20 mg) or interruptions
of cabozantinib or matched placebo treatment were allowed for un-
acceptable adverse events (AEs). Dose modiﬁcation details are further
summarized in the Appendix.
End Points and Assessments
The primary end point was OS. The secondary end point was BSR at
week 12, deﬁned as a decrease of 30% or more in bone scan lesion area
from baseline to week 12, which was evaluated by a central independent
radiology review committee.29 Progressive disease on bone scan was de-
ﬁned as an increase of more than 30% from baseline in bone scan lesion
area in areas attributable to metastatic disease or at least two new areas of
radiotracer uptake attributable to metastatic disease in regions of bone not
previously showing radiotracer uptake. Further information on BSR mea-
surement and assessment is provided in the Appendix. Radiographic PFS
(rPFS) was determined according to RECIST (version 1.1).30
Exploratory efﬁcacy assessments included rPFS per investigator
assessment, changes in CTCs, bone biomarkers, circulating PSA, and symp-
tomatic skeletal events (SSEs). Exploratory end point assessments are
summarized in the Appendix.
Safety assessments included monitoring of AEs and serious AEs
(SAEs), deaths, standard laboratory test results, physical examination ﬁnd-
ings, and ECG recordings. Safety was assessed at least every 3 weeks up to
week 12 (based on date of ﬁrst dose) and every 6 weeks thereafter. AE terms
were mapped to system organ class and preferred terms using the Medical
Dictionary for Regulatory Activities (version 16.1). The seriousness, severity
grade, and relationship of AEs to study treatment were assessed by the in-
vestigator, and severity grade was deﬁned by the Common Terminology
Criteria for Adverse Events (version 4.0).
Statistical Methods and Analysis
The study assumed a 7.0-month median OS for the control group
based on the observed OS in the COU-AA-301 study.12 On the basis
of a random assignment ratio of two to one of cabozantinib to pred-
nisone, 578 deaths were required to provide 90% power to detect an
HR of 0.75 (median OS, 7.0 months in prednisone group v 9.3 months
in cabozantinib group) using the log-rank two-sided test at an overall
type I error level of 0.05.
The primary analysis of OS was conducted using the intent-to-treat
population. The median duration of OS and the associated 95% CI for
each treatment group were estimated using the Kaplan-Meier method.
Inference testing was conducted using the log-rank test, stratiﬁed by the
same factors used to stratify the random assignment. The HR and 95% CI
were estimated using a Cox proportional hazards model, with treatment
group as the independent variable, and stratiﬁed by random assignment
stratiﬁcation factors. P values are presented without control for multiple
comparisons.
The percentage dose-intensity of cabozantinib was calculated as
100 3 (average daily dose [mg/day])/(60 mg/day), and the percentage
3006 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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dose-intensity of prednisone was calculated as 100 3 (average daily
dose [mg/day])/(10 mg/day). Analysis plans for secondary or ex-
ploratory end points and prespeciﬁed subgroups are described in the
Appendix.
Prespeciﬁed subgroup analyses for both the primary and secondary
end points evaluated the inﬂuence of baseline and demographic charac-
teristics on outcomes, including region (North America, Europe, or
Australia), prior cabazitaxel therapy (yes v no), visceral metastases (yes v
no), baseline Brief Pain Inventory item 3 (, 4 v$ 4), ECOG PS (0 to 1 v 2),
and lactate dehydrogenase (# upper limit of normal v . upper limit
of normal).
RESULTS
Patients
Between July 2, 2012, and November 14, 2014, 1,028 patients
were enrolled at 216 centers across 14 countries in Europe (76%),
North America (15%), and Australia (6%). Baseline characteristics
were balanced between treatment groups (Table 1). A majority of
patients were age 65 years or older, white, and enrolled in Europe.
Random assignment stratiﬁcation factors were balanced between
treatment groups.
Patient disposition is summarized in Figure 1. A total of 1,023
patients received treatment: 680 received cabozantinib, and 343
received prednisone. As of July 7, 2014, 91% of patients in the
cabozantinib group and 95% in the prednisone group had dis-
continued study treatment. Discontinuations because of AEs were
more common with cabozantinib (33%) than with prednisone
(12%). Discontinuations because of progressive disease were more
common with prednisone (37%) than with cabozantinib (19%).
Other primary reasons for discontinuation were similar between
treatment groups.
OS
The primary and ﬁnal OS analysis was conducted after 614
events had occurred. Median OS estimated by Kaplan-Meier
methods was 11.0 months for cabozantinib and 9.8 months for
prednisone. No signiﬁcant difference in OS between cabozantinib
and prednisone was observed (HR, 0.90; 95% CI, 0.76 to 1.06;
stratiﬁed log-rank P = .213; Fig 2A). Prespeciﬁed subgroup ana-
lyses for OS are summarized in the Appendix (Appendix Fig A1,
online only).
Table 1. Baseline Demographic and Clinical Characteristics
Characteristic
No. (%)
Cabozantinib
(n = 682)
Prednisone
(n = 346)
Age, years
Median 69.5 69.0
Range 35-87 43-89
Race
White 520 (76) 265 (77)
Not reported 140 (21) 71 (21)
Black or African American 14 (2) 6 (2)
Asian 2 (0.3) 0
American Indian or Alaska
native
0 1 (0.3)
Other 6 (0.9) 3 (0.9)
Time from diagnosis to study
entry, years
Median 6.68 6.98
Range 0.09-26.6 0.04-22.2
ECOG PS
0 or 1 605 (89) 303 (88)
2 76 (11) 43 (12)
Missing 1 (0.1) 0
Gleason score . 7 at diagnosis 298 (44) 162 (47)
Bone scan lesion area, mm2
Median 45,635.5 41,746.0
Range 0-388,052 0-283,304
Extent of metastasis
None 0 0
Bone 681 (100) 346 (100)
Soft tissue
Lymph node 313 (46) 140 (40)
Visceral 133 (20) 58 (17)
Liver 91 (13) 35 (10)
Lung 69 (10) 29 (8)
Other soft tissue 39 (6) 23 (7)
BPI worst pain $ 4 284 (42) 148 (43)
Opioid narcotic use within last
24 hours
454 (67) 228 (66)
No. of prior anticancer agents*
2 57 (8) 31 (9)
$ 3 625 (92) 315 (91)
Time from end of most recent
prior systemic anticancer
therapy to random
assignment, weeks
Median 4.71 4.14
Range 229.1-77.4 0.7-66.9
Received prior docetaxel 682 (100) 346 (100)
Total cumulative dose, mg/m2
Median 615.0 613.0
Range 140-5,625 225-5,400
Duration of treatment, months
Median 5.68 5.73
Range 0.95-59.10 1.28-52.04
Received prior abiraterone 626 (92) 320 (92)
Duration of treatment, months
Median 6.93 7.51
Range 0.03-39.06 0.10-62.59
Received prior enzalutamide 168 (25) 91 (26)
Duration of treatment, months
Median 4.04 4.90
Range 0.82-41.46 0.07-34.53
Received prior docetaxel and
abiraterone and
enzalutamide
112 (16) 66 (19)
Prior radiation therapy for CRPC† 488 (72) 251 (73)
(continued in next column)
Table 1. Baseline Demographic and Clinical Characteristics (continued)
Characteristic
No. (%)
Cabozantinib
(n = 682)
Prednisone
(n = 346)
Concomitant bisphosphonates or
denosumab
329 (48) 171 (49)
Patients who had SSE before
study random assignment
354 (52) 188 (54)
Abbreviations: BPI, Brief Pain Inventory; CRPC, castration-resistant prostate
cancer; ECOG PS, Eastern Cooperative Oncology Group performance status;
SSE, symptomatic skeletal event.
*Excluding agents to maintain castration status.
†Excluding radionucleotides.
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BSR
BSR at week 12 per independent radiology review committee
was 42% (95% CI, 38% to 46%) with cabozantinib and 3% (95%
CI, 1% to 5%) with prednisone (unstratiﬁed and stratiﬁed
Cochran-Mantel-Haenszel P, .001 for both; Table 2). For patients
with a BSR (n = 286), median duration of BSR (calculated from
date of ﬁrst BSR to date of bone scan progression) was 5.8 months
(95% CI, 5.5 to 8.3) with cabozantinib and 1.8 months (95% CI,
0.62 to not estimable) with prednisone.
PFS
Cabozantinib was associated with improvements in investigator-
determined rPFS. Median rPFS was 5.6 months with cabozantinib
and 2.8 months with prednisone (HR, 0.48; 95% CI, 0.40 to 0.57;
stratiﬁed log-rank P , .001; Fig 2B). Subsequent therapies received
after progressionweremore common in the cabozantinib arm than in
the prednisone arm (Table 3).
Skeletal-Related Events
Fifty-two percent of patients in the cabozantinib group and
54% of patients in the prednisone group had experienced one or
more SSEs before study entry. Cabozantinib treatment was asso-
ciated with an increase in time to ﬁrst SSE (HR, 0.62; 95% CI, 0.48
to 0.81; stratiﬁed log-rank P, .001; Fig 2C) and with lower rates of
SSEs during study (cabozantinib, 14%; prednisone, 21%; Appendix
Table A1, online only). Radiotherapy to bone was themost common
SSE in both groups (cabozantinib, 12%; prednisone, 18%).
CTCs, Bone Biomarkers, and PSA
The favorable CTC conversion rate (deﬁned as$ ﬁve CTCs at
baseline to , ﬁve CTCs as best postbaseline result) was 33% for
cabozantinib and 6% for prednisone (Appendix Table A2, online
only). Cabozantinib treatment was also associated with improvement
in bone-speciﬁc alkaline phosphatase, N-terminal cross-linked telo-
peptides of type I collagen, and C-terminal cross-linked telopeptides
of type I collagen (Appendix Table A3, online only). Cabozantinib
treatment was not associated with improved PSA response or time to
PSA progression. A PSA response, deﬁned as a reduction of 50% or
more in PSA level, occurred in 6% of cabozantinib-treated patients
and 2% of prednisone-treated patients. The median time to PSA
progression was 4.2 and 3 months with cabozantinib and prednisone,
respectively (unstratiﬁed HR, 0.95; P = .639).
Safety
The median duration of study drug treatment was 20.1 weeks
(range, 0.6 to 92.1 weeks) for cabozantinib and 12.3 weeks (range,
Randomly assigned
(ITT population)  (n = 1,028)
Screened   (N = 1,311)
Did not pass screening      (n = 283)
Continued study treatment
(safety population)  (n = 59)
Lost to follow-up
Protocol violation
Other
Primary reason for discontinuing study treatment*
Adverse event
Clinical deterioration
Progressive disease
Patient withdrawal
Physician decision
No treatment administered
Sponsor decision
(n = 228; 33%)
(n = 227; 33%)
(n = 132; 19%)
(n = 18; 3%)
(n = 9; 1%)
(n = 2; 0.3%)
(n = 2; 0.3%)
(n = 1; 0.1%)
(n = 1; 0.1%)
(n = 1; 0.1%)
Received study treatment
(safety population) (n = 680; 100%)
Cabozantinib        (n = 682)
Primary reason for discontinuing study treatment*
Adverse event
Clinical deterioration
Progressive disease
Patient withdrawal
Physician decision
No treatment administered
Sponsor decision
Lost to follow-up
Protocol violation
Other
(n = 42; 12%)
(n = 133; 38%)
(n = 128; 37%)
(n = 14; 4%)
(n = 7; 2%)
(n = 3; 0.9%)
(n = 0)
(n = 0)
(n = 0)
(n = 2; 0.6%)
Prednisone             (n = 346)
Received study treatment
(safety population)  (n = 343; 99%)
Continued study treatment
(safety population)   (n = 14)
Fig 1. CONSORT diagram. ITT, intent to
treat. (*) As of July 7, 2014.
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No.
(events)
Median (months)
(95% CI)
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HR (95% CI) P* 
No.
(events)
Median (months)
(95% CI)
Stratified
HR (95% CI) P* 
No.
(events)
Median (months)
(95% CI)
Stratified
HR (95% CI) P* 
682Cabozantinib 11.0 .2130.90
(403) (10.1 to 11.6) (0.76 to 1.06)
682 616 505 392 183 74 16 2Cabozantinib
No. at risk
346Prednisone 306 244 183 84 29 7 0
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Cabozantinib
Prednisone
Time (months)
0 3 6 9 12 15 18 21 24
346Prednisone 2.8
(220) (2.8 to 2.9)
682Cabozantinib 6.6 < .0010.48
(375) (5.5 to 5.6) (0.40 to 0.57)
No. at risk
682 353 153 70 21 10 3 1Prednisone
346Cabozantinib 90 29 9 4 1 0 0
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Cabozantinib
Prednisone
Time (months)
0 3 6 9 12 15 18 21 24
346Prednisone NE
(100) (NE to NE)
682Cabozantinib NE < .0010.62
(139) (NE to NE) (0.48 to 0.81)
682 561 426 313 159 62 18 3Cabozantinib
No. at risk
346Prednisone 254 182 127 70 23 8 1
Fig 2. Kaplan-Meier plots of (A) overall survival,
(B) radiographic progression-free survival, and (C)
time to ﬁrst symptomatic skeletal event (SSE). HR,
hazard ratio; NE, not estimable. (*) Stratiﬁed log-
rank test.
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2.0 to 71.1 weeks) for prednisone. The median percentage dose-
intensity was 75% for cabozantinib and 100% for prednisone.
The most common AEs in both groups are listed in Table 4.
SAEs were reported by 62% and 53% of patients in the cabo-
zantinib and prednisone groups, respectively. The following SAEs
occurred at an incidence of at least 2% higher with cabozantinib
compared with prednisone: pulmonary embolism (6.2% v 0.9%),
vomiting (4.1% v 1.8%), fatigue (2.9% v 0.9%), and dehydration
(2.9% v 0.3%).
Study drug discontinuations because of AEs were reported
for 33% and 12% of patients in the cabozantinib and pred-
nisone groups, respectively (Appendix Table A4, online only).
AEs leading to dose reductions or interruptions were reported
for 88% and 45% of patients in the cabozantinib and pred-
nisone groups, respectively, and AEs that led to dose reductions
were reported for 67% and 15% of patients, respectively. The
median time to ﬁrst dose level reduction was 47.5 days (range,
6 to 379 days) and 44 days (range, 22 to 344 days) in the
cabozantinib and prednisone groups, respectively. AEs leading
to dose modiﬁcations are summarized in Appendix Table A5
(online only).
Grade 5 AEs occurring within 30 days of the last study drug
dose were reported in 15% and 13% of patients in the cabo-
zantinib and prednisone groups, respectively, and were most
commonly considered disease related. Deaths considered not
related to prostate cancer and occurring within 30 days of the
last study dose are summarized in the Appendix.
DISCUSSION
In this randomized, controlled trial of men with mCRPC and
bone metastases with disease progression after docetaxel and
abiraterone acetate and/or enzalutamide, cabozantinib did not
signiﬁcantly improve OS compared with prednisone. Consis-
tent with observations from phase II studies,25,26 cabozantinib
was associated with improvements in other study outcomes,
including BSR, rPFS, SSEs, CTCs, and bone biomarkers, but not
PSA outcomes.
The primary results of this study are consistent with the
published results of sunitinib, an orally available TKI that in-
hibits VEGF receptor 2 but not MET. In phase II studies of
patients with mCRPC, sunitinib was observed to have modest
effects on bone scans and bone biomarkers.31 In a phase III ran-
domized controlled trial of patients with mCRPC and disease
progression after docetaxel, sunitinib did not improve OS
compared with placebo (HR, 0.914; 95% CI, 0.762 to 1.097;
P = .168).32 Sunitinib was associated with signiﬁcant improvement
in PFS (HR, 0.725; 95% CI, 0.591 to 0.890; P , .001) and higher
rates of study drug discontinuation because of AEs (27% v 7%)
compared with placebo. The phase III sunitinib study did not
report effects on bone scans, CTCs, or bone biomarkers. Other
compounds targeting VEGF and angiogenesis, such as bev-
acizumab, aﬁlbercept, and lenalidomide, have also failed to
improve OS in patients with mCRPC when combined with
docetaxel.33-35 No signiﬁcant anticancer activity was detected
with the MET-targeting agent rilotumumab when combined
with mitoxantrone.36
In metastatic prostate cancer, CTC counts at baseline
have prognostic value, and changes during therapy have been
considered predictive of treatment beneﬁt.37-39 Furthermore,
higher CTC counts have been observed in patients with bone
metastases compared with those without bone metastases.37,40
In our study, a higher incidence of CTC conversion, from ﬁve
or more cells at baseline (indicative of unfavorable prognosis)
to fewer than ﬁve cells postbaseline (indicative of favorable
prognosis), in the cabozantinib group compared with the
prednisone group was observed. These ﬁndings, along with
favorable changes in other biomarkers, except PSA, support
the hypothesis that cabozantinib treatment was associated
with biologic activity affecting both tumor cells and the bone
microenvironment.
The biologic activities of cabozantinib are diverse, with
bone effects, direct effects on cancer cells, and antiangiogenic
effects being demonstrated in preclinical models.21-23 It could
be argued that the observed changes in BSR, bone biomarkers,
Table 2. Bone Scan Response at Week 12 per IRC
Response
No. (%)
Cabozantinib
(n = 682)
Prednisone
(n = 346)
Best overall response
Responder 288 (42) 9 (3)
Stable bone scan 136 (20) 102 (29)
Progressive bone
scan
66 (10) 129 (37)
Unable to evaluate 0 0
Missing* 192 (28) 106 (31)
BSR at week 12 288 (42) 9 (3)
95% CI 38% to 46% 1% to 5%
Stratiﬁed CMH P† , .001
Unstratiﬁed CMH P† , .001
Abbreviations: BSR, bone scan response; CMH, Cochran-Mantel-Haenszel;
IRC, independent radiology review committee.
*Indicates no qualifying baseline or postbaseline assessment.
†P value was obtained using the CMH test (adjusted for stratiﬁcation factors, if
applicable).
Table 3. Concomitant and Subsequent Nonprotocol Anticancer Therapy
Received
Therapy
No. (%)
Cabozantinib
(n = 682)
Prednisone
(n = 346)
Any anticancer therapy 374 (55) 236 (68)
Systemic nonirradiation anticancer therapy 258 (38) 175 (51)
Local nonirradiation therapy 28 (4) 10 (3)
Any radiation therapy (including
radionuclides)
176 (26) 116 (34)
Any medications* 373 (55) 236 (68)
Cabazitaxel* 95 (14) 78 (23)
Enzalutamide* 137 (20) 75 (22)
External-beam radiation therapy* 84 (12) 69 (20)
Docetaxel* 17 (2.5) 30 (8.7)
Abiraterone acetate* 37 (5.4) 26 (7.5)
Radium-223 chloride/alpharadin* 42 (6.2) 19 (5.5)
*With $ 5% incidence in any treatment arm.
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and SSEs in our study are consistent with biologic effects in
bone and bone metastases, and the improvements in CTCs
suggest a direct antitumor effect, although the lack of im-
provement in PSA outcomes argues against such an effect. On
the basis of phase II study results, it was clear that the effects of
cabozantinib on intermediate end points were complex and in
some cases contradictory. For these reasons, OS was selected as
the primary study end point.
The cabozantinib dose selected in this trial was based on
ﬁndings from a phase II expansion cohort in patients with mCRPC
who received either 100 or 40 mg of cabozantinib per day.27 Both
doses showed activity in late-stage mCRPC, with improved
tolerability at the 40-mg dose. In another study, the 40-mg
dose showed substantial pharmacodynamic activity for BSR,
whereas activity seemed markedly attenuated at a 20-mg dose.41
Therefore, a dose of 60 mg per day was selected for phase III
investigation in mCRPC as an active dose that could be reduced
to 40 mg for tolerability while still maintaining pharmacody-
namic activity.
Safety data in this trial were consistent with those observed in
earlier-stage cabozantinib trials in mCRPC,25,27 and no new or
unexpected AEs occurred. Adverse effects typically associated with
VEGF inhibition and/or TKI use, such as hypertension, fatigue,
and palmar-plantar erythrodysesthesia syndrome, were observed at
higher rates with cabozantinib compared with prednisone. The
pulmonary embolism incidence with cabozantinib was consistent
with that previously described in phase II trials in patients with
mCRPC treated with agents targeting the VEGF pathway.25,27
Dehydration was also observed in this population, and this may
have been associated with the higher incidence of GI disorders (eg,
diarrhea, nausea, and vomiting) with cabozantinib treatment.
Sixty-seven percent of patients had AEs that led to dose reductions,
a rate lower than that observed in a phase III trial of a higher dose
of cabozantinib (140 mg/day) in patients with metastatic med-
ullary thyroid cancer, whereas the rate of treatment discontinua-
tion because of AEs with cabozantinib was substantially higher in
our study (33% v 16%).42 These results indicate insufﬁcient tol-
erability of the 60-mg dose of cabozantinib in our older patient
population with heavily pretreated mCRPC, and lower doses
and/or more proactive management of AEs should be considered
in future investigations.
It is unclear why improvements in BSR, rPFS, SSEs, CTC
conversions, and bone biomarkers with cabozantinib did not
translate into signiﬁcantly improved OS in this population of
patients with late-stage mCRPC. Notably, the relationship be-
tween intermediate outcomes and OS may vary from drug to
Table 4. Summary of Frequently-Reported AEs Occurring in $ 10% of Patients in Either Treatment Group
AE
No. (%)
Cabozantinib
(n = 681)
Prednisone
(n = 342)
All Grades Grades 3 to 4 All Grades Grades 3 to 4
Patients with one or more AE 680 (100) 481 (71) 333 (97) 191 (56)
Decreased appetite 411 (60) 55 (8.1) 100 (29) 7 (2.0)
Nausea 394 (58) 47 (6.9) 106 (31) 7 (2.0)
Diarrhea 353 (52) 50 (7.3) 70 (20) 5 (1.5)
Fatigue 347 (51) 119 (17) 120 (35) 30 (8.8)
Vomiting 278 (41) 38 (5.6) 70 (20) 8 (2.3)
Asthenia 238 (35) 84 (12) 64 (19) 21 (6.1)
Weight decreased 237 (35) 23 (3.4) 41 (12) 2 (0.6)
Constipation 232 (34) 7 (1.0) 104 (30) 3 (0.9)
Anemia 208 (31) 108 (16) 113 (33) 61 (18)
PPE syndrome 200 (29) 39 (5.7) 5 (1.5) 0
Hypertension 195 (29) 135 (20) 39 (11) 24 (7.0)
Dysphonia 182 (27) 0 21 (6.1) 0
Dysgeusia 175 (26) 1 (0.1) 16 (4.7) 0
Dyspnea 141 (21) 24 (3.5) 49 (14) 4 (1.2)
Mucosal inﬂammation 137 (20) 22 (3.2) 9 (2.6) 0
Stomatitis 127 (19) 18 (2.6) 8 (2.3) 0
Back pain 122 (18) 29 (4.3) 67 (20) 13 (3.8)
Bone pain 118 (17) 35 (5.1) 68 (20) 23 (6.7)
Edema peripheral 102 (15) 5 (0.7) 44 (13) 3 (0.9)
Pain in extremity 102 (15) 18 (2.6) 37 (11) 3 (0.9)
Arthralgia 94 (14) 16 (2.3) 53 (15) 9 (2.6)
Hypothyroidism 94 (14) 0 1 (0.3) 0
General physical health deterioration 90 (13) 53 (7.8) 32 (9.4) 20 (5.8)
Headache 88 (13) 3 (0.4) 17 (5.0) 3 (0.9)
Abdominal pain 80 (12) 13 (1.9) 19 (5.6) 6 (1.8)
Urinary tract infection 79 (12) 15 (2.2) 33 (9.6) 7 (2.0)
Pyrexia 78 (11) 4 (0.6) 39 (11) 2 (0.6)
Aspartate aminotransferase 71 (10) 14 (2.1) 14 (4.1) 4 (1.2)
Hypokalemia 71 (10) 26 (3.8) 9 (2.6) 2 (0.6)
Pain 62 (9.1) 18 (2.6) 38 (11) 19 (5.6)
Musculoskeletal pain 46 (6.8) 7 (1.0) 37 (11) 3 (0.9)
Abbreviations: AE, adverse event; PPE, palmar-plantar erythrodysesthesia.
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drug. Alternatively, the lack of a signiﬁcant OS beneﬁt despite
improvements in a variety of other intermediate outcomes may
have resulted from high rates of treatment discontinuation be-
cause of AEs, confounding effects of subsequent salvage therapies,
the use of an active comparator, unidentiﬁed imbalances in
prognostic factors between treatment arms, and/or limitations
of intermediate end points for assessment of certain targeted
therapies.
METoverexpression has been shown to be more common in
metastatic sites compared with primary prostate cancer samples.43
Aberrant expression of hepatocyte growth factor, the MET ligand,
has also been shown to promote tumor progression in preclin-
ical studies, and high plasma levels of hepatocyte growth factor
have been correlated with poor outcomes in patients with prostate
cancer.44,45 The successful development of cabozantinib in mCRPC
may require a speciﬁc biomarker evaluation to identify patients
with a high likelihood of treatment beneﬁt.
In summary, cabozantinib did not signiﬁcantly improve
OS in patients with mCRPC and disease progression after do-
cetaxel and abiraterone acetate and/or enzalutamide. Cabozantinib
was not associated with improvements in PSA outcomes. How-
ever, improvements in other study outcomes, including BSR,
rPFS, time to ﬁrst SSE, CTC conversions, and bone biomarkers,
are notable.
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Appendix
Exclusion Criteria
Exclusion criteria included receipt of any anticancer agent apart from agents to maintain castration status within 2 weeks before
random assignment, radiation therapy within 4 weeks or radionuclide therapy within 6 weeks of random assignment, and known
brain metastases or cranial epidural disease.
Random Assignment and Blinding
Random assignment was conducted using an interactive voice record system or interactive Web record system. Treatment
assignment was not known to patients, investigators, study centers, the sponsor, or any study-afﬁliated personnel other than those
authorized to access treatment assignment for regulatory safety reporting and submission processes, interactive voice record system
or interactive Web record system administration, or drug supply management. Cabozantinib-matched placebo was packaged
and color-, size-, and shape-matched to be indistinguishable from cabozantinib. Prednisone tablets were commercially obtained
and overencapsulated in hard gelatin capsule shells to blind product identity. Prednisone-matched placebo capsules were color- and
size-matched to the overencapsulated prednisone.
Dose Reductions and Modifications
Dose reduction or interruption was recommended for intolerable grade 2 toxicities that could not be adequately managed or
for grade 3 toxicities apart from clinically nonrelevant laboratory abnormalities. A patient experiencing grade 4 toxicities apart from
clinically nonrelevant laboratory abnormalities was to have immediate interruption of dosing and to be permanently discontinued
from the trial unless the patient was deriving clear clinical beneﬁt from therapy as determined by the investigator or if the toxicity
could be managed with a dose reduction after recovery to grade 1 or less and optimal medical care. Dose modiﬁcations or
interruptions may have occurred with a lower-grade toxicity if it was in the interest of patient safety.
Bone Scan Response
Whole-body anterior and posterior bone scans were acquired on all patients approximately 3 hours (6 15 minutes) after
intravenous administration of 25 mCi (6 10%) of a technetium-99 bone-seeking radiopharmaceutical. The same tracer, tracer
dose, and delay from injection to scanning were used for an individual patient across the study. Computed tomography scans
included full coverage of the chest, abdomen, and pelvis at screening and every 12 weeks after random assignment. If a magnetic
resonance imaging scan was performed for the abdominal and pelvic examinations, a noncontrast computed tomography chest
scan was also performed. The same modality and imaging protocol used at baseline were to be used at all subsequent imaging time
points. All study images acquired both on and off schedule were provided by the study site to the independent review committee
(IRC) for independent evaluation. Site-speciﬁc image acquisition guidelines were provided separately by the IRC. In addition,
available clinical information that could have inﬂuenced the interpretation of radiographic images was to be documented at the
time of tumor assessments. Each scan analysis was read and conﬁrmed visually by two independent core board-certiﬁed nuclear
medicine physicians or radiologists, using quantitative computer-aided detection software, adjudicated by a third blinded nuclear
medicine physician if the two primary readers disagreed on key parameters.
A response of unevaluable was assigned if bone scan results could not be interpreted because of inconsistent image acquisition
parameters compared with the reference scan, incomplete imaging, or other technical deﬁciencies. Stable disease was deﬁned as not
meeting the criteria for response, progressive disease, or unable to evaluate.
Assessment of Circulating Tumor Cells and Bone Biomarkers
Serial blood samples were collected for enumerations of circulating tumor cells (CTCs) and bone biomarkers bone-
speciﬁc alkaline phosphatase (BSAP) and N-terminal and C-terminal cross-linked telopeptides of type I collagen at baseline
and at the end of weeks 6 and 12. Patients were partitioned into the following CTC categories at baseline: fewer than ﬁve CTCs
per 7.5 mL of blood versus ﬁve or more. CTCs per 7.5 mL of blood. Patients with ﬁve or more CTCs at baseline were assessed
for conversion to fewer than ﬁve CTCs at weeks 6 and/or 12, and patients with fewer than ﬁve CTCs at baseline were assessed
for conversion to ﬁve or more CTCs at weeks 6 and/or 12. For bone biomarkers (BSAP and N-terminal and C-terminal
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cross-linked telopeptides of type I collagen), patients were assessed for best change (greatest decrease or lowest increase) at
weeks 6 and/or 12.
Assessment of Skeletal-Related Events
Symptomatic skeletal events (SSEs) were deﬁned as any one of the following: radiation therapy to bone including the use of
bone-targeted radiopharmaceuticals, pathologic fracture, spinal cord compression, or bone surgery. Any SSEs occurring in the
previous 12 months or within a longer timeframe but that were considered clinically signiﬁcant were recorded at baseline. For
postbaseline assessments, the investigator determined whether an SSE had occurred, and a description of the event was recorded.
Assessment of Overall Survival
Duration of overall survival was deﬁned as the time from random assignment to death resulting from any cause. For patients
who were alive at the time of data cutoff or who were permanently lost to follow-up, duration of overall survival was right-censored
at the earlier of the data cutoff date or the date the patient was last known to be alive.
Subgroup Analyses
Prespeciﬁed subgroup analyses for both the primary and secondary end points evaluated the inﬂuence of baseline and
demographic characteristics on outcome, including region (North America, Europe, or Australia), prior cabazitaxel therapy (yes v
no), visceral metastases (yes v no), baseline Brief Pain Inventory item 3 (, 4 v $ 4), Eastern Cooperative Oncology Group
performance status (0 to 1 v 2), lactate dehydrogenase (# upper limit of normal [ULN] v. ULN), prednisone use (yes v no), bone
scan lesion area (, median v $ median), BSAP (# ULN v . ULN), CTCs (, v, $ 5), and prostate-speciﬁc antigen (PSA)
(, median v $ median).
Assessment of Secondary End Point
For the secondary analysis of the proportion of patients experiencing a bone scan response (BSR) according to IRC assessment
at the end of week 12, a stratiﬁed two-sided Cochran-Mantel-Haenszel test at the .05 level of signiﬁcance was used to compare the
two treatment groups, using the same stratiﬁcation factors as those used for the random assignment schedule. A gatekeeping
strategy for analysis of the secondary efﬁcacy end point controlled the family-wise error rate at 0.05.
Assessment of Exploratory End Points
Each exploratory end point was analyzed using an appropriate two-sided statistical test without adjustment for multiplicity.
Exploratory analyses of BSR included best BSR at any time point and duration of BSR. The hazard ratio was estimated using a Cox
regression model with treatment arm as the only main effect and stratifying by the same stratiﬁcation factors used for random
assignment. Descriptive statistics were performed for CTC conversion, and categorical analyses were also performed. The median
time to ﬁrst SSE and the associated 95% CI for each treatment arm were estimated using the Kaplan-Meier method.
PSA Responses
Blood samples for PSA analysis were collected at screening, the end of week 12 after the date of random assignment, and every
12 weeks thereafter and assessed at a central laboratory.
Causes of Death Through 30 Days of Last Dose of Study Drug
The most common causes of death (occurring in $ two patients in either treatment arm) through 30 days of the last dose of
study drug were prostate cancer (cabozantinib, n = 50; prednisone, n = 26), general physical health deterioration (n = 14; n = 1),
death not otherwise speciﬁed (n = 4; n = 1), sepsis (n = 3; n = 1), euthanasia (n = 3; n = 0), pulmonary embolism (n = 3; n = 0),
multiorgan failure (n = 2; n = 2), pneumonia (n = 2; n = 1), renal failure (n = 2; n = 1), septic shock (n = 2; n = 1), respiratory failure
(n = 2; n = 0), cardiac failure (n = 1; n = 1), and sudden death (n = 1; n = 1).
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Table A1. SSEs
SSE
No. (%)
Cabozantinib
(n = 682)
Prednisone
(n = 346)
Patient incidence of any post–random assignment SSE 98 (14) 71 (21)
Radiation therapy to bone 81 (12) 63 (18)
Spinal cord compression 19 (3) 15 (4)
Pathologic fractures 12 (2) 7 (2)
Surgery to bone 9 (1) 7 (2)
NOTE. Bone-targeted therapies consist of bisphosphonates or denosumab. Treatment-emergent SSEs recorded from the adverse event case report form page;
categories are not mutually exclusive. For the determination of patient incidence, only the ﬁrst event per patient was counted. The denominator includes the shortest of
the following durations: time from ﬁrst dose to an event, time from ﬁrst dose to data cutoff, or time from ﬁrst dose until 30 days after last dose.
Abbreviation: SSE, symptomatic skeletal event.
Table A2. Changes in CTCs Compared With Baseline
CTCs
No. (%)
Cabozantinib (n = 682) Prednisone (n = 346)
Baseline Week 6 Week 12 Best Postbaseline* Baseline Week 6 Week 12 Best Postbaseline*
All patients
, 5 cells/7.5 mL blood 170 (25) 264 (39) 189 (28) 324 (48) 104 (30) 78 (23) 58 (17) 100 (29)
$ 5 cells/7.5 mL blood postbaseline — 10 (6) 15 (9) 9 (5) — 22 (21) 25 (24) 20 (19)
$ 5 cells/7.5 mL blood 435 (64) 217 (32) 203 (30) 250 (37) 211 (61) 184 (53) 126 (36) 199 (58)
, 5 cells/7.5 mL blood postbaseline — 109 (25) 78 (18) 142 (33) — 9 (42) 6 (3) 13 (6)
Patients with $ 5 cells/7.5 mL blood at baseline
$ 30% decrease postbaseline — 222 (51) 161 (37) 269 (62) — 37 (18) 17 (8) 56 (37)
$ 50% decrease postbaseline — 202 (46) 147 (34) 250 (57) — 23 (11) 9 (4) 33 (16)
$ 70% decrease postbaseline — 167 (38) 119 (37) 211 (49) — 9 (4) 5 (2) 12 (6)
Abbreviation: CTC, circulating tumor cell.
*Best postbaseline value deﬁned as the smallest value across week 6 and week 12 postbaseline visits.
Table A3. Changes in Serum Bone Markers Compared With Baseline
Bone Marker
Cabozantinib Prednisone
Baseline Week 6 Week 12 Best Change* Baseline Week 6 Week 12 Best Change*
BSAP, % change from baseline
No. of patients 452 366 302 383 246 205 152 216
Median — 23.99 2.20 210.01 — 18.99 28.28 11.20
Range — 289.9-557.4 290.6-347.4 294.0-557.4 — 264.3-1,121.6 264.5-439.5 264.5-1,121.6
Serum NTx, % change from baseline†
No. of patients 455 370 310 386 240 202 147 209
Median — 215.35 26.74 223.56 — 0 15.38 0
Range — 285.0-359.2 285.9-299.7 286.1-281.8 271.6-946.2 256.4-386.2 271.6-946.2
Serum CTx, % change from baseline†
No. of patients 440 356 292 372 239 201 147 209
Median — 22.78 0 212.28 — 0 0 0
Range — 286.6-162.7 286.5-225.0 288.4-132.5 — 272.4-1,166.5 254.9-703.5 272.4-1,166.5
Abbreviations: BSAP, bone-speciﬁc alkaline phosphatase; CTx, C-terminal cross-linked telopeptides of type I collagen; NTx, N-terminal cross-linked telopeptides of type I
collagen; LLQ, lower limit of quantitation.
*Best change was the largest decrease, or smallest increase if no decrease was observed, at weeks 6 and 12 from baseline.
†NTx and CTx percentages were based on patients with baseline value $ LLQ. Regarding patients , LLQ at baseline, no patient in the cabozantinib arm or the
prednisone arm converted to $ LLQ at any time postbaseline. For BSAP, all but one patient was $ LLQ at baseline.
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Table A4. AEs Leading to Study Drug Discontinuation in $ 1% of Patients in Either Treatment Arm Regardless of Relationship to Disease Progression
AE
No. (%)
Cabozantinib
(n = 681)
Prednisone
(n = 342)
Fatigue 54 (7.9) 14 (4.1)
General physical health deterioration 50 (7.3) 17 (5.0)
Asthenia 34 (5.0) 6 (1.8)
Nausea 29 (4.3) 8 (2.3)
Decreased appetite 28 (4.1) 10 (2.9)
Diarrhea 20 (2.9) 2 (0.6)
Vomiting 18 (2.6) 3 (0.9)
Pulmonary embolism 17 (2.5) 1 (0.3)
Palmar-plantar erythrodysaesthesia
syndrome
15 (2.2) 0
Prostate cancer 14 (2.1) 9 (2.6)
Anemia 12 (1.8) 7 (2.0)
Weight decreased 11 (1.6) 4 (1.2)
Dehydration 11 (1.6) 0
Bone pain 10 (1.5) 16 (4.7)
Back pain 8 (1.2) 11 (3.2)
Stomatitis 8 (1.2) 0
Metastatic pain 7 (1.0) 4 (1.2)
Spinal cord compression 7 (1.0) 4 (1.2)
Arthralgia 7 (1.0) 2 (0.6)
Dyspnea 7 (1.0) 2 (0.6)
Pain 5 (0.7) 4 (1.2)
Thrombocytopenia 5 (0.7) 4 (1.2)
Pyrexia 4 (0.6) 4 (1.2)
Aspartate aminotransferase increased 2 (0.3) 4 (1.2)
Musculoskeletal pain 1 (0.1) 4 (1.2)
Abbreviation: AE, adverse event.
Table A5. AEs Leading to Dose Modiﬁcation in $ 5% of Patients in Either Treatment Arm
AE
No. (%)
Cabozantinib
(n = 681)
Prednisone
(n = 342)
No. of patients with $ one AE leading to dose modiﬁcation 600 (88) 154 (45)
Decreased appetite 144 (21) 14 (4.1)
Diarrhea 144 (21) 8 (2.3)
Fatigue 141 (21) 21 (6.1)
Nausea 135 (20) 12 (3.5)
Asthenia 122 (18) 11 (3.2)
Palmar-plantar erythrodyaesthesia syndrome 104 (15) 0
Vomiting 103 (15) 12 (3.5)
Hypertension 73 (11) 2 (0.6)
Mucosal inﬂammation 52 (7.6) 0
Weight decreased 49 (7.2) 4 (1.2)
Stomatitis 45 (6.6) 0
General physical health deterioration 34 (5.0) 10 (2.9)
Abbreviation: AE, adverse event.
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Subgroup
Region
Prior cabazitaxel
Baseline pain severity
Baseline ECOG PS
Visceral metastases
Baseline LDH
0.25 0.5 1 2
Australia 35 27
Europe 528 256
No 421 214
Yes 261 132
All patients 682 346
North America 119 63
< 4 389 196
≥ 4 284 148
0 to 1 605 303
2 76 43
No 549 288
Yes 133 58
≤ ULN 353 288
>  ULN 325 158
Prednisone
better
Cabozantinib
better
Cabozantinib 
No. of Patients Unstratified HR for 
Death (95% CI)
Prednisone
0.56
0.95
1.01
0.76
0.91
0.94
0.83
0.99
0.91
0.95
0.90
0.77
0.89
0.89
(0.29 to 1.06)
(0.78 to 1.15)
(0.81 to 1.28)
(0.60 to 0.97)
(0.77 to 1.07)
(0.64 to 1.39)
(0.66 to 1.05)
(0.78 to 1.25)
(0.76 to 1.10)
(0.63 to 1.43)
(0.75 to 1.09)
(0.54 to 1.09)
(0.69 to 1.17)
(0.72 to 1.11)
Fig A1. Forest plot of overall survival by subgroup categories. ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate
dehydrogenase; ULN, upper limit of normal.
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